Effect of metformin and sitagliptin on doxorubicin-induced cardiotoxicity in rats

Impact of oxidative stress, inflammation, and apoptosis

Mina Thabet Kelleni, Entesar Farghaly Amin, Aly Mohamed Abdelrahman

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Doxorubicin (DOX) is a widely used antineoplastic drug whose efficacy is limited by its cardiotoxicity. The aim of this study was to investigate the possible protective role of the antidiabetic drugs metformin (250 mg/kg dissolved in DW p.o. for seven days) and sitagliptin (10 mg/kg dissolved in DW p.o. for seven days) in a model of DOX-induced (single dose 15 mg/kg i.p. at the fifth day) cardiotoxicity in rats. Results of our study revealed that pretreatment with metformin or sitagliptin produced significant (P < 0.05) cardiac protection manifested by a significant decrease in serum levels of LDH and CK-MB enzymes and cardiac MDA and total nitrites and nitrates levels, a significant increase in cardiac SOD activity, and remarkable improvement in the histopathological features as well as a significant reduction in the immunohistochemical expression of COX-2, iNOS, and caspase-3 enzymes as compared to DOX group. These results may suggest using metformin and/or sitagliptin as preferable drugs for diabetic patients suffering from cancer and receiving DOX in their chemotherapy regimen.

Original languageEnglish
Article number424813
JournalJournal of Toxicology
Volume2015
DOIs
Publication statusPublished - 2015

Fingerprint

Oxidative stress
Metformin
Doxorubicin
Rats
Oxidative Stress
Apoptosis
Inflammation
Chemotherapy
Enzymes
Nitrites
Hypoglycemic Agents
Caspase 3
Antineoplastic Agents
Nitrates
Drug Therapy
Sitagliptin Phosphate
Cardiotoxicity
Serum
Pharmaceutical Preparations
Neoplasms

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

Effect of metformin and sitagliptin on doxorubicin-induced cardiotoxicity in rats : Impact of oxidative stress, inflammation, and apoptosis. / Kelleni, Mina Thabet; Amin, Entesar Farghaly; Abdelrahman, Aly Mohamed.

In: Journal of Toxicology, Vol. 2015, 424813, 2015.

Research output: Contribution to journalArticle

@article{1cfb88292f894626adb70b0f92195e65,
title = "Effect of metformin and sitagliptin on doxorubicin-induced cardiotoxicity in rats: Impact of oxidative stress, inflammation, and apoptosis",
abstract = "Doxorubicin (DOX) is a widely used antineoplastic drug whose efficacy is limited by its cardiotoxicity. The aim of this study was to investigate the possible protective role of the antidiabetic drugs metformin (250 mg/kg dissolved in DW p.o. for seven days) and sitagliptin (10 mg/kg dissolved in DW p.o. for seven days) in a model of DOX-induced (single dose 15 mg/kg i.p. at the fifth day) cardiotoxicity in rats. Results of our study revealed that pretreatment with metformin or sitagliptin produced significant (P < 0.05) cardiac protection manifested by a significant decrease in serum levels of LDH and CK-MB enzymes and cardiac MDA and total nitrites and nitrates levels, a significant increase in cardiac SOD activity, and remarkable improvement in the histopathological features as well as a significant reduction in the immunohistochemical expression of COX-2, iNOS, and caspase-3 enzymes as compared to DOX group. These results may suggest using metformin and/or sitagliptin as preferable drugs for diabetic patients suffering from cancer and receiving DOX in their chemotherapy regimen.",
author = "Kelleni, {Mina Thabet} and Amin, {Entesar Farghaly} and Abdelrahman, {Aly Mohamed}",
year = "2015",
doi = "10.1155/2015/424813",
language = "English",
volume = "2015",
journal = "Journal of Toxicology",
issn = "1687-8191",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Effect of metformin and sitagliptin on doxorubicin-induced cardiotoxicity in rats

T2 - Impact of oxidative stress, inflammation, and apoptosis

AU - Kelleni, Mina Thabet

AU - Amin, Entesar Farghaly

AU - Abdelrahman, Aly Mohamed

PY - 2015

Y1 - 2015

N2 - Doxorubicin (DOX) is a widely used antineoplastic drug whose efficacy is limited by its cardiotoxicity. The aim of this study was to investigate the possible protective role of the antidiabetic drugs metformin (250 mg/kg dissolved in DW p.o. for seven days) and sitagliptin (10 mg/kg dissolved in DW p.o. for seven days) in a model of DOX-induced (single dose 15 mg/kg i.p. at the fifth day) cardiotoxicity in rats. Results of our study revealed that pretreatment with metformin or sitagliptin produced significant (P < 0.05) cardiac protection manifested by a significant decrease in serum levels of LDH and CK-MB enzymes and cardiac MDA and total nitrites and nitrates levels, a significant increase in cardiac SOD activity, and remarkable improvement in the histopathological features as well as a significant reduction in the immunohistochemical expression of COX-2, iNOS, and caspase-3 enzymes as compared to DOX group. These results may suggest using metformin and/or sitagliptin as preferable drugs for diabetic patients suffering from cancer and receiving DOX in their chemotherapy regimen.

AB - Doxorubicin (DOX) is a widely used antineoplastic drug whose efficacy is limited by its cardiotoxicity. The aim of this study was to investigate the possible protective role of the antidiabetic drugs metformin (250 mg/kg dissolved in DW p.o. for seven days) and sitagliptin (10 mg/kg dissolved in DW p.o. for seven days) in a model of DOX-induced (single dose 15 mg/kg i.p. at the fifth day) cardiotoxicity in rats. Results of our study revealed that pretreatment with metformin or sitagliptin produced significant (P < 0.05) cardiac protection manifested by a significant decrease in serum levels of LDH and CK-MB enzymes and cardiac MDA and total nitrites and nitrates levels, a significant increase in cardiac SOD activity, and remarkable improvement in the histopathological features as well as a significant reduction in the immunohistochemical expression of COX-2, iNOS, and caspase-3 enzymes as compared to DOX group. These results may suggest using metformin and/or sitagliptin as preferable drugs for diabetic patients suffering from cancer and receiving DOX in their chemotherapy regimen.

UR - http://www.scopus.com/inward/record.url?scp=84957075791&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957075791&partnerID=8YFLogxK

U2 - 10.1155/2015/424813

DO - 10.1155/2015/424813

M3 - Article

VL - 2015

JO - Journal of Toxicology

JF - Journal of Toxicology

SN - 1687-8191

M1 - 424813

ER -